Wednesday, October 14, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 28, 2026

Jim Cramer says Warren Buffett is wrong about investors being addicted to 'gambling' — they're addicted to the S&P 500

View original at finance.yahoo.com
Jim Cramer says Warren Buffett is wrong about investors being addicted to 'gambling' — they're addicted to the S&P 500 Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Zero days to expiration (0DTE) options are not investing or speculating — they are pure gambling because they involve placing quick wagers on tiny price moves over just a few hours

    60% confidence

  • Speculation is not limited to gambling on individual stocks — it is a growing issue across all levels of the market including instruments traditionally considered safe

    60% confidence

  • Investors have been trained to love ETFs indiscriminately regardless of what kind they are

    60% confidence

  • Investors are addicted to buying the S&P 500 regardless of market conditions, not to gambling on individual stocks

    60% confidence

  • The denigration of individual stock investing has made markets more casino-like; if individual stock picking had been respected, speculation would be lower

    60% confidence

  • Markets have never felt this speculative and people have never been in a more gambling mood

    60% confidence

  • Current markets resemble a church with a casino attached, and the casino side has grown very crowded while the speculative instruments have become progressively more attractive

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com